Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:0571-86130357     Add to Favorites | Online Feedback 中文
新闻中心 / News Center
Betta Pharmaceuticals and Xcovery to co-develop a new generation ALK inhibitor
Form: betta   Date: 2014-10-25

        Hangzhou, China (October 25th 2014) – Betta Pharmaceuticals and Xcovery announce in Hangzhou today that Xcovery will get an equity investment worth 20 million dollars from Betta Pharmaceuticals. As the leading enterprise in new drug research and development of China, Betta continues to exert efforts in research and development of new drugs after successfully completed the development and marketing of Icotinib Hydrochloride. Located in Florida,U.S.A., Xcovery is a R&D enterprise focusing on development of new generation anti-tumor targeted drugs. Its key program, X-396, is a new generation ALK inhibitor directed at lung cancer, which is now under Phase 1/2 clinical research in the United States. Apart from equity investment, Betta will also get the development right of the X-396 program in China. 


Prev: The Achievement of the “11th, 12th Five-Year Plan” New Drug Research and Development Major Program – The Academic Conference for the 3rd Anniversary of the release of Conmana was held in Hangzhou
Next: The Company successfully passed the ISO14001/18001 Certification